<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00537680</url>
  </required_header>
  <id_info>
    <org_study_id>SNT-III-002</org_study_id>
    <nct_id>NCT00537680</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia</brief_title>
  <acronym>IONIA</acronym>
  <official_title>A Phase III Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santhera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santhera Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is meant to assess the effectiveness of idebenone on neurological outcome measures
      in patients with Friedreich's Ataxia over a 6 months period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study involves 6 clinic visits and upon completion the possibility to join a 12 months
      extension study where all patients will receive high dose Idebenone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICARS</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>International Cooperative Ataxia Rating Scale (ICARS):
ICARS consists of a one-hundred-point semi-quantitative scale based upon 19 simple testing manoeuvres compartmentalized into postural and stance disorders, limb ataxia, dysarthria and oculomotor disorders and has been previously used in this patient population with good inter-rater reliability.
Scores for each subscale quantify the extent of ataxia in each clinically important area. Subscale scores are summed to give a total score ranging from 0 (best) to 100 (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FARS</measure>
    <time_frame>6 Months</time_frame>
    <description>Friedreich's Ataxia Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADL of FARS</measure>
    <time_frame>6 Months</time_frame>
    <description>ADL=Activities of Daily Living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACT</measure>
    <time_frame>6 Months</time_frame>
    <description>Friedreich's Ataxia Composite Test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Friedreich's Ataxia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mid dose Idebenone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose Idebenone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idebenone</intervention_name>
    <description>Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients &gt; 45 kg/99 lbs: idebenone 900 mg/day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idebenone</intervention_name>
    <description>Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients &gt; 45 kg/99 lbs: idebenone 2250 mg/day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Documented diagnosis of Friedreich's Ataxia (FRDA) with confirmed FRDA mutations

          -  Patients 8 - 17 years of age at baseline

          -  Patients with a body weight greater than 25 kg/55 lbs at baseline

          -  Patients able to walk at least 10 meters without accompanying person (ICARS Walking
             Capacities score ≤6) at screening and baseline

          -  Patients who in the opinion of the investigator are able to comply with the
             requirements of the study, including swallowing the study medication

          -  Negative urine pregnancy test at screening and baseline (female patients of
             childbearing potential)

        Exclusion criteria:

          -  Treatment with idebenone, Coenzyme Q10 or vitamin E (if taken at a dose 5 times above
             the daily requirement) within the past month

          -  Patients with International Cooperative Ataxia Rating Scale (ICARS) score of greater
             than 54 or less than 10 at screening

          -  Pregnancy and/or breast-feeding

          -  Clinically significant abnormalities of clinical hematology or biochemistry including,
             but not limited to, elevations greater than 1.5 times the upper limit of normal of
             Aspartate Aminotransferase (AST; also known as GOT), Alanine Aminotransferase (ALT;
             also known as GPT) or creatinine

          -  History of abuse of drugs or alcohol

          -  Participation in the previous (Phase II) study of idebenone at the National Institutes
             of Health (NIH)

          -  Participation in a trial of another investigational drug within the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Perlman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Lynch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Geffen School of Medicine, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hopsital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol. 2012 Feb;259(2):284-91. doi: 10.1007/s00415-011-6174-y. Epub 2011 Jul 22.</citation>
    <PMID>21779958</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2007</study_first_submitted>
  <study_first_submitted_qc>September 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2007</study_first_posted>
  <results_first_submitted>June 7, 2011</results_first_submitted>
  <results_first_submitted_qc>November 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2011</results_first_posted>
  <last_update_submitted>February 2, 2012</last_update_submitted>
  <last_update_submitted_qc>February 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Friedreich's Ataxia</keyword>
  <keyword>Idebenone</keyword>
  <keyword>ICARS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idebenone</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mid Dose Idebenone</title>
          <description>25 kg/55 lbs to ≤45 kg/99 lbs: idebenone 450 mg/day (1 x 150 mg tablet, t.i.d.) &gt;45 kg/99 lbs: idebenone 900 mg/day (2 x 150 mg tablet, t.i.d.)</description>
        </group>
        <group group_id="P2">
          <title>High Dose Idebenone</title>
          <description>25 kg/55 lbs to ≤45 kg/99 lbs: idebenone 1350 mg/day (2 x 150 mg tablet, t.i.d.) &gt;45 kg/99 lbs: idebenone 2250 mg/day (2 x 150 mg tablet, t.i.d.)</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mid Dose Idebenone</title>
          <description>25 kg/55 lbs to ≤45 kg/99 lbs: idebenone 450 mg/day (1 x 150 mg tablet, t.i.d.) &gt;45 kg/99 lbs: idebenone 900 mg/day (2 x 150 mg tablet, t.i.d.)</description>
        </group>
        <group group_id="B2">
          <title>High Dose Idebenone</title>
          <description>25 kg/55 lbs to ≤45 kg/99 lbs: idebenone 1350 mg/day (2 x 150 mg tablet, t.i.d.) &gt;45 kg/99 lbs: idebenone 2250 mg/day (2 x 150 mg tablet, t.i.d.)</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.93" spread="2.54"/>
                    <measurement group_id="B2" value="13.44" spread="3.03"/>
                    <measurement group_id="B3" value="13.69" spread="2.77"/>
                    <measurement group_id="B4" value="13.68" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ICARS</title>
        <description>International Cooperative Ataxia Rating Scale (ICARS):
ICARS consists of a one-hundred-point semi-quantitative scale based upon 19 simple testing manoeuvres compartmentalized into postural and stance disorders, limb ataxia, dysarthria and oculomotor disorders and has been previously used in this patient population with good inter-rater reliability.
Scores for each subscale quantify the extent of ataxia in each clinically important area. Subscale scores are summed to give a total score ranging from 0 (best) to 100 (worst).</description>
        <time_frame>baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mid Dose Idebenone</title>
            <description>25 kg/55 lbs to ≤45 kg/99 lbs: idebenone 450 mg/day (1 x 150 mg tablet, t.i.d.) &gt;45 kg/99 lbs: idebenone 900 mg/day (2 x 150 mg tablet, t.i.d.)</description>
          </group>
          <group group_id="O2">
            <title>High Dose Idebenone</title>
            <description>25 kg/55 lbs to ≤45 kg/99 lbs: idebenone 1350 mg/day (2 x 150 mg tablet, t.i.d.) &gt;45 kg/99 lbs: idebenone 2250 mg/day (2 x 150 mg tablet, t.i.d.)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>ICARS</title>
          <description>International Cooperative Ataxia Rating Scale (ICARS):
ICARS consists of a one-hundred-point semi-quantitative scale based upon 19 simple testing manoeuvres compartmentalized into postural and stance disorders, limb ataxia, dysarthria and oculomotor disorders and has been previously used in this patient population with good inter-rater reliability.
Scores for each subscale quantify the extent of ataxia in each clinically important area. Subscale scores are summed to give a total score ranging from 0 (best) to 100 (worst).</description>
          <units>ICARS points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="6.3"/>
                    <measurement group_id="O2" value="-2.4" spread="4.8"/>
                    <measurement group_id="O3" value="-1.3" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FARS</title>
        <description>Friedreich’s Ataxia Rating Scale</description>
        <time_frame>6 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADL of FARS</title>
        <description>ADL=Activities of Daily Living</description>
        <time_frame>6 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FACT</title>
        <description>Friedreich’s Ataxia Composite Test</description>
        <time_frame>6 Months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>&quot;0&quot; means none.</desc>
      <group_list>
        <group group_id="E1">
          <title>Mid Dose Idebenone</title>
          <description>25 kg/55 lbs to ≤45 kg/99 lbs: idebenone 450 mg/day (1 x 150 mg tablet, t.i.d.) &gt;45 kg/99 lbs: idebenone 900 mg/day (2 x 150 mg tablet, t.i.d.)</description>
        </group>
        <group group_id="E2">
          <title>High Dose Idebenone</title>
          <description>25 kg/55 lbs to ≤45 kg/99 lbs: idebenone 1350 mg/day (2 x 150 mg tablet, t.i.d.) &gt;45 kg/99 lbs: idebenone 2250 mg/day (2 x 150 mg tablet, t.i.d.)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal &amp; connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Thomas Meier</name_or_title>
      <organization>Santhera Pharmaceuticals</organization>
      <phone>+41619068964</phone>
      <email>thomas.meier@santhera.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

